Array acquires worldwide rights to encorafenib from Novartis

23 January 2015

Oncology specialist Array Biopharma (Nasdaq: ARRY) has reached an agreement with Swiss drug major Novartis (NOVN: VX) to acquire the worldwide rights to encorafenib (LGX818).

Encorafenib is a BRAF inhibitor currently in Phase III development. The agreement is conditional on the closing of transactions between Novartis and GlaxoSmithKline (LSE: GSK) last April, which are expected to close in the first half of 2015, and also on the receipt of regulatory approvals.

This comes after a definitive agreement in which Array will regain global rights from Novartis to the Phase III MEK inhibitor binimetinib. In order to fulfil competition requirements for the European Commission, Array has agreed to take on a partner for global development and European commercialization of binimetinib and encorafenib.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK